Early Adjuvant Results A Major Boost For Verzenio
Commercially Important Indication
Pioneering results in early disease could prove significant for market prospects for Lilly’s CDK4/6 breast cancer drug.
You may also be interested in...
White said the late 2019 creation of Loxo Oncology at Lilly to spearhead cancer R&D has exceeded her expectations. The executive also discussed COVID-19’s impact on drug sales and cancer screening.
Results from a large Swedish study provide further evidence that mixing different COVID-19 vaccines boosts effectiveness. Meanwhile, Japan plans new funding to support the home-grown development of coronavirus and other vaccines.
Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.